LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Emergency 3-Dimensional-Printed Devices for Splitting Ventilators in Lungs With Different Compliances: An In Vitro Study.

    Frizzera-Borges, Marcelo / Frizzera, Fausto / Lemos, Jório B M / Carraretto, Antônio R

    A&A practice

    2021  Volume 15, Issue 3, Page(s) e01392

    Abstract: Ventilator shortages occurred due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This in vitro study evaluated the effectiveness of 3-dimensional (3D)-printed splitters and 3D-printed air flow limiters (AFL) in delivering ... ...

    Abstract Ventilator shortages occurred due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This in vitro study evaluated the effectiveness of 3-dimensional (3D)-printed splitters and 3D-printed air flow limiters (AFL) in delivering appropriate tidal volumes (TV) to lungs with different compliances. Groups were divided according to the size of the AFL: AFL-4 was a 4-mm device, AFL-5 a 5-mm device, AFL-6 a 6-mm device, and no limiter (control). A ventilator was split to supply TV to 2 artificial lungs with different compliances. The AFL improved TV distribution.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/therapy ; Emergency Medical Services/methods ; Humans ; Lung/physiology ; Lung Compliance/physiology ; Male ; Printing, Three-Dimensional ; Tidal Volume/physiology ; Ventilators, Mechanical/supply & distribution
    Language English
    Publishing date 2021-03-09
    Publishing country United States
    Document type Journal Article
    ISSN 2575-3126
    ISSN (online) 2575-3126
    DOI 10.1213/XAA.0000000000001392
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011.

    Bognar, Cinthia Leite Frizzera Borges / Simon, Sergio Daniel / Gansl, Rene Claudio / Abramoff, Roberto / Aisen, Marcelo / Lopes Junior, Gilberto de Lima / Smaletz, Oren / Peres, Stela Verzinhasse / Tabacof, Jacques

    Einstein (Sao Paulo, Brazil)

    2015  Volume 13, Issue 2, Page(s) 215–220

    Abstract: Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.: Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a ... ...

    Abstract Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.
    Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature.
    Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference.
    Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Adenocarcinoma of Lung ; Adult ; Aged ; Aged, 80 and over ; Brazil ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/genetics ; Erlotinib Hydrochloride ; Female ; Follow-Up Studies ; Hospitals, General ; Hospitals, Proprietary ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Mutation/genetics ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Retrospective Studies ; Sex Distribution ; Survival Rate ; Treatment Outcome
    Chemical Substances Protein Kinase Inhibitors ; Quinazolines ; Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1)
    Language Portuguese
    Publishing date 2015-07-08
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 2418293-X
    ISSN 2317-6385 ; 1679-4508
    ISSN (online) 2317-6385
    ISSN 1679-4508
    DOI 10.1590/S1679-45082015AO3326
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011

    Cinthia Leite Frizzera Borges Bognar / Sergio Daniel Simon / Rene Claudio Gansl / Roberto Abramoff / Marcelo Aisen / Gilberto de Lima Lopes Junior / Oren Smaletz / Stela Verzinhasse Peres / Jacques Tabacof

    Einstein (São Paulo), Vol 13, Iss 2, Pp 215-220

    Abstract: ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a ... ...

    Abstract ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.
    Keywords Carcinoma pulmonar de células não pequenas ; Genes erbB-1 ; Receptor do fator de crescimento epidérmico ; Inibidores de proteínas quinases ; Antineoplásicos ; Medicine ; R
    Subject code 610 ; 616
    Language English
    Publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top